North America held 40% share in global market and dominated the metabolomics market in 2015.This region remains competitive with the presence of a large number of vendors. Europe was the second largest market with over 30% share of the total share in the same year. Asia Pacific is expected to witness rapid growth in the years to come.
Zion Research has published a new report titled “Metabolomics Market by Technology (Mass Spectrometry, Capillary Electrophoresis, High Performance Liquid Chromatography, Gas Chromatography, and Nuclear Magnetic Resonance Spectroscopy), Indication (Cardiology and Oncology) for Drug Discovery, Biomarker and Nutrigenomics : Global Industry Perspective, Comprehensive Analysis and Forecast, 2015 – 2021”. According to the report, the global demand for metabolomics was valued at over USD 675.0 million in 2015 and it is expected to reach above USD 2,500.0 million in 2021, growing at a CAGR of above 25.0% between 2016 and 2021.
Metabolites are substances or compounds found in the cell, they are intermediate products catalyzed by enzymes in the metabolism process. Signaling molecules, hormones, metabolic intermediates and secondary metabolites are some of the types of metabolites. Metabolism is the process to maintain living state of cell. Metabolism can be either anabolism or catabolism. Anabolism is the process in which certain compounds are synthesized that is required for cells to process, while breakdown of molecules for releasing energy is the catabolism. Metabolome is total set of metabolites present in a single organism. Metabolomics is study of chemical reactions related to metabolites and a field of analytical biochemistry. Metabolomics is used to compute and recognize the metabolites present in the cell via analytical technologies together with multi variant and statistical method for data interpretation.
Browse the full “Metabolomics Market by Technology (Mass Spectrometry, Capillary Electrophoresis, High Performance Liquid Chromatography, Gas Chromatography, and Nuclear Magnetic Resonance Spectroscopy), Indication (Cardiology and Oncology) for Drug Discovery, Biomarker and Nutrigenomics: Global Industry Perspective, Comprehensive Analysis, Size, Share, Growth, Segment, Trends and Forecast, 2015 – 2021”
Increasing scope of toxicological studies, clinical trials, rise in awareness for health and government and institution funds for research is expected to drive the demand for the metabolomics market. Lack of adoption of metabolomics technology and complexity of the process can hamper the metabolomics market. Increasing research and development expenditure and existing demand from emerging economies and is likely to open new market avenues in the near future.
The metabolomics market is segmented on the basis of technology, indication, application and region. Mass spectrometry, capillary electrophoresis, high performance liquid chromatography, gas chromatography and nuclear magnetic resonance spectroscopy are some of the major segments based on technology. High performance liquid chromatography was largest technology segment for metabolomics market. Drug discovery, biomarker and nutrigenomics are some of the key application markets for metabolomics. Drug discovery emerged as dominating segment due to its significant role in optimization, prioritization and drug target validation and identification for research. Cardiology and oncology are the indication for metabolomics.
Key players in global metabolomics market include Danaher Corporation, Bruker Corporation, Waters Corporation, Metabolon, Inc., Agilent Technologies, Thermo Fisher Scientific and Shimadzu Corporation among others.